Synopsys Undervalued as Market Overlooks AI Revenue Opportunity, Morgan Stanley Says

Morgan Stanley raised its price target for Synopsys to $574 from $500, forecasting fiscal 2027 EPS of $19.12. The firm believes Synopsys' AI story isn't fully priced in, but a re-rating depends on execution and proof of usage revenue growth. Investors will watch for metrics like customer retention and contracted backlog.

Morgan Stanley raised Synopsys' (SNPS) price target to $574 from $550, citing AI growth potential. SNPS shares dipped 0.8% premarket. GF Value™ estimates intrinsic value at $661.95, 32.8% above current price. SNPS has a GF Score™ of 93/100, reflecting strong growth and profitability. The stock's P/E ratio is 78.61x, below its 5-year median of 59.07x.

Morgan Stanley raised its price target for Synopsys (SNPS) to $574, citing AI-driven expansion. The firm believes Synopsys' valuation discount is unwarranted. Shares fell 0.8% in premarket trading.

Morgan Stanley raised its price target for Synopsys to $574 from $500. The company's stock is currently trading at $454.58, down 9.54% year-to-date. Additionally, an insider sold shares worth $6.76 million, according to an SEC filing.

Synopsys (SNPS) saw its price target raised by Needham following its investor day. The firm reportedly presented positively, with a notable announcement involving GPT-Synopsys, though details were not provided in the summary. This update may influence investor perceptions and trading activity.

Needham raised its price target on Synopsys to $620 from $580. The company's stock is currently trading at $509.99, with a 5-day change of +2.46% and a year-to-date change of +8.57%. Synopsys is also working to comply with US export rules using Chinese models.